Tweenvest Stocks

The Greater Cannabis Company, Inc. (OTCPK: GCAN)

Health Care · Pharmaceuticals · US

$0.25

+8.78% today · -35.8% 1Y

The Greater Cannabis Company, Inc. (OTCPK: GCAN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $236.52K and employs 1 people.

Over the last twelve months the share price has lost 35.8%, trading between 0.04 and 0.67.

Tweenvest scores The Greater Cannabis Company, Inc. across four factors: quality 14/100. Its strongest factor is quality.

GCAN price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$236.52K
Revenue (TTM)
P/E
0.26
EPS
0.96
Dividend yield
Beta (5Y)
0.34
52-week high
$0.67
52-week low
$0.04
Avg volume (3M)
Shares outstanding
944.93K
Employees
1
Next earnings

About The Greater Cannabis Company, Inc.

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.

ISIN
US3916572023
Founded
2014
Listed since
Sep 18, 2018
Exchange
Pink Sheets LLC
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.12T$1,257.35+0.16%
Johnson & JohnsonNYSE: JNJ$651.25B$271.37+0.42%
Merck & Co., Inc.NYSE: MRK$376.37B$152.55+2.39%
Roche Holding AGSWX: ROP$373.91BCHF370.90-1.25%
Novartis AGSWX: NOVN$302.17BCHF127.42+0.85%
AstraZeneca PLCLSE: AZN$258.76B£121.48-0.76%
Novo Nordisk A/SCPSE: NOVO B$207.84BDkr300.85+1.59%
Pfizer Inc.NYSE: PFE$159.99B$28.15+0.29%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.